We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Integer (ITGR) Q1 Earnings
Read MoreHide Full Article
The upcoming report from Integer (ITGR - Free Report) is expected to reveal quarterly earnings of $1.27 per share, indicating an increase of 11.4% compared to the year-ago period. Analysts forecast revenues of $431.84 million, representing an increase of 4.1% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 1.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Integer metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' at $162.26 million. The estimate indicates a year-over-year change of +3.8%.
According to the collective judgment of analysts, 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' should come in at $22.58 million. The estimate indicates a change of -22.5% from the prior-year quarter.
Analysts expect 'Sales- Medical Sales- Cardio & Vascular' to come in at $247.02 million. The estimate points to a change of +11.4% from the year-ago quarter.
Shares of Integer have experienced a change of -1.5% in the past month compared to the -8.9% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ITGR is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Integer (ITGR) Q1 Earnings
The upcoming report from Integer (ITGR - Free Report) is expected to reveal quarterly earnings of $1.27 per share, indicating an increase of 11.4% compared to the year-ago period. Analysts forecast revenues of $431.84 million, representing an increase of 4.1% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 1.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Integer metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' at $162.26 million. The estimate indicates a year-over-year change of +3.8%.
According to the collective judgment of analysts, 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' should come in at $22.58 million. The estimate indicates a change of -22.5% from the prior-year quarter.
Analysts expect 'Sales- Medical Sales- Cardio & Vascular' to come in at $247.02 million. The estimate points to a change of +11.4% from the year-ago quarter.
View all Key Company Metrics for Integer here>>>
Shares of Integer have experienced a change of -1.5% in the past month compared to the -8.9% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ITGR is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>